You are here

T-Vec

Amgen's Imlygic May Not Boost Earnings But It Will Change Cancer Care

Forbes

Wed, 10/28/15 - 09:17 am

Amgen's First-of-its-Kind Skin Cancer Drug Wins U.S. Approval

Bloomberg

Tue, 10/27/15 - 09:25 pm

Amgen's T-Vec inches toward EU approval for melanoma

Fierce Biotech

Fri, 10/23/15 - 11:06 am

Next-gen oncolytics upstart Replimune grabs a $30M transatlantic venture round

Fierce Biotech

Thu, 09/24/15 - 11:44 am

FDA Panel Gives Thumbs-Up To Amgen's Virus-Based Melanoma Drug

Forbes

Wed, 04/29/15 - 06:31 pm

Talimogene Laherparepvec

FDA review challenges Amgen on a questionable T-Vec study

Fierce Biotech

Mon, 04/27/15 - 09:46 am

Talimogene Laherparepvec

cancer vaccines

Will FDA advisers shoot down Amgen's cancer vaccine?

Fierce Biotech

Thu, 02/12/15 - 02:15 pm

What You Need to Know About Amgen's Oncology Line-Up

Motley Fool

Thu, 01/23/14 - 09:52 am

Amgen melanoma drug improved survival by 21 pct in interim look

Reuters

Sat, 06/1/13 - 12:12 pm

Talimogene Laherparepvec